Zydus buys Assertio for $166m to scale US brands

Deal in focus: Zydus picks Assertio in an all-cash offer

Zydus Lifesciences has agreed to acquire US-based Assertio Holdings through its subsidiary Zydus Worldwide DMCC and an acquisition vehicle, Zara Merger Sub Inc. The transaction is an all-cash deal valued at about $166.4 million (around Rs 1,570 crore). Zydus is offering $13.50 per share in cash for all outstanding Assertio shares. The acquisition is positioned as a way to give Zydus a ready-made branded-drugs commercial platform in the United States. It also strengthens Zydus’ specialty pharmaceutical presence, particularly in pain management and oncology-support therapies.

The agreement follows a competitive process in which Assertio had previously signed a merger agreement with Garda Therapeutics. Assertio’s board later concluded Zydus’ proposal provided better value and stronger execution certainty. Zydus, for its part, has framed the acquisition as a step beyond its traditional strength in generics and toward higher-margin specialty and branded products.

What Zydus is paying and how the premium stacks up

Zydus’ $13.50-per-share offer represents a 30.6% premium to Garda Therapeutics’ earlier $18-per-share offer announced on April 8, 2026. It is also a 7.8% premium to Garda’s revised $11.80-per-share bid announced on May 4. The offer is described as 75.8% higher than Assertio’s unaffected closing share price on March 20, 2026, before unusual trading activity and sharp stock movement began.

For Assertio shareholders, the structure and certainty of funding were central to the board’s decision. Assertio said Zydus’ bid has no financing contingencies, requires no third-party financing, and is fully guaranteed by a Zydus entity. That guarantee was highlighted as giving Assertio “direct recourse” in the event of a breach or failure to close.

Why Assertio matters: a US branded-drugs platform

A key strategic rationale cited by Zydus is immediate access to Assertio’s marketing and distribution network in the world’s largest pharmaceutical market. Assertio markets a portfolio of branded prescription products in the US. The deal gives Zydus an established commercial setup rather than requiring a buildout from scratch.

Zydus said it plans to leverage Assertio’s commercial infrastructure and oncology relationships to expand its specialty oncology presence in the US. The acquisition is described as strengthening Zydus’ specialty pharmaceutical presence, particularly in pain management and oncology-support therapies. This is also presented as a way to reduce reliance on the intensely competitive generics segment.

Rolvedon and oncology-support: the product anchor

Assertio’s portfolio includes Rolvedon, described as a long-acting treatment used to reduce infection risk in cancer patients undergoing chemotherapy. Rolvedon is approved by the US Food and Drug Administration as a long-acting G-CSF biologic for the prevention of febrile neutropenia in adult cancer patients receiving myelosuppressive chemotherapy.

Zydus’ stated plan is to use Assertio’s oncology relationships to broaden its specialty oncology presence in the US. The company’s emphasis on oncology-support therapies highlights the commercial value of differentiated, branded products with established physician relationships and distribution pathways.

How the deal structure works: tender offer followed by merger

The transaction is structured as a tender offer followed by a merger. Under the terms described, Zydus will promptly commence a tender offer to acquire all outstanding Assertio common stock for $13.50 per share in cash, without interest. The closing is subject to customary conditions, including the tender of a majority of Assertio’s outstanding shares.

Following completion of the tender offer, Zydus will acquire any remaining shares through a second-step merger at the same $13.50-per-share price. Once completed, Assertio will be delisted from Nasdaq. Assertio also said it expects to file a Form 8-K with the US Securities and Exchange Commission summarising key terms, and a Schedule 14D-9 in connection with the tender offer.

Timelines: FY27 mention vs “second quarter of 2026” expectation

The timeline is described in two ways across the statements included in the material. Zydus said the deal is expected to close in FY27, subject to customary closing conditions. Separately, coverage attributed to Dow Jones Newswires said the deal is expected to close in the second quarter, and Assertio’s transaction overview also said it is expected to close in the second quarter of 2026.

Assertio added that no regulatory approvals are expected to be required. The company also noted that the tender offer had not yet commenced at the time of its communication.

What changed at Assertio: Garda agreement terminated

Before Zydus’ approach prevailed, Assertio had an earlier merger agreement with Garda Therapeutics. The Assertio board determined Zydus’ offer constituted a “Superior Proposal” under the Garda merger agreement and authorised the company to terminate the Garda agreement announced on May 4, 2026.

The stated reason was a combination of higher value and execution certainty. The absence of financing contingencies and the full guarantee by a Zydus entity were cited as key factors in the board’s assessment.

Why this matters for Indian pharma: moving beyond US generics

Zydus’ acquisition is framed as part of a broader shift among Indian drugmakers. The article notes Indian companies have increasingly been looking to build specialty portfolios in the US to reduce dependence on generics, where pricing pressure has intensified over the past few years. In that context, Assertio offers Zydus a direct presence in branded prescriptions and a specialty oncology commercial platform.

The deal also highlights a segment where Indian drugmakers have historically had limited direct presence: specialty oncology commercial operations in the US. By buying an established platform, Zydus is effectively buying time, relationships, and distribution capacity alongside product rights.

Recent US-focused moves around Zydus: deals, approvals, and reported talks

Zydus Lifesciences Managing Director Sharvil Patel said the Assertio transaction would strengthen the company’s specialty and oncology footprint in the US and help it build “differentiated, durable specialty businesses globally.” Beyond the Assertio announcement, the material also references other US-focused developments around Zydus.

One report said Zydus is evaluating an acquisition of a majority stake in US-based Ardelyx Inc. in a deal likely valued at $1.2-2.5 billion, and funded through a Rs 5,000-crore equity raise via a qualified institutional placement (QIP) and internal cash accruals. Another version of the Ardelyx coverage described the company as valued at $1.6 billion and said Zydus could pursue either a controlling stake or a key molecule acquisition, with the QIP proposal having board approval dated November 6, 2025.

Separately, Sentynl Therapeutics, Zydus’ US subsidiary, received USFDA approval for ZYCUBO (copper histidinate), described as the first treatment for Menkes disease in the United States. The material also notes that on Jan. 15, 2026, Zydus announced the successful closure of agreements with Agenus Inc., including CFIUS clearance, and said acquired manufacturing assets and operations would be housed under a newly formed US-based subsidiary, Zylidac Bio LLC.

Key numbers and terms at a glance

Analysis: why the platform is as important as the products

The transaction’s logic rests on commercial capabilities in the US as much as on Assertio’s portfolio. By acquiring a company with an existing marketing and distribution setup, Zydus gains infrastructure that can support additional specialty launches over time. Zydus also highlighted oncology relationships as a lever to expand its specialty oncology presence, signalling that customer access and field capabilities are central to the acquisition thesis.

The premiums paid relative to Garda’s bids, and relative to the unaffected share price, show the value assigned to certainty and speed of execution. Assertio’s board explicitly pointed to the absence of financing contingencies and the full guarantee by a Zydus entity. That emphasis suggests closing risk was a meaningful differentiator in the process.

Conclusion: what to watch next

Zydus’ $166.4 million all-cash deal for Assertio marks a clear push toward branded and specialty medicines in the US, anchored by an established commercial platform and oncology-support products such as Rolvedon. The transaction is expected to proceed via a tender offer followed by a merger, subject to customary closing conditions and majority tender of shares. With Assertio set to be delisted from Nasdaq after completion, the next milestones will be the tender offer launch and the closing timeline indicated as the second quarter of 2026 in the transaction overview.